Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect 2021 Virtual Conference

Rhea-AI Summary

Aldeyra Therapeutics (Nasdaq: ALDX) announced that CEO Todd C. Brady will participate in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference. The chat is scheduled for January 11, 2021, at 6:00 a.m. ET, and will be accessible on the company's website. This event will be archived for 90 days. Aldeyra is a clinical-stage biotechnology company focused on developing novel therapies for immune-mediated diseases, with investigational compounds such as reproxalap and ADX-629, targeting reactive aldehyde species in inflammatory diseases.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect 2021 Virtual Conference.

The fireside chat will be available beginning at 6:00 a.m. ET Monday, January 11, 2021 on the Investors & Media section of the Aldeyra Therapeutics website at https://ir.aldeyra.com. The event will remain archived on the website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210108005281/en/

FAQ

What time does Aldeyra's fireside chat at H.C. Wainwright BioConnect 2021 start?

The fireside chat begins at 6:00 a.m. ET on January 11, 2021.

Where can I watch Aldeyra's fireside chat?

The chat can be viewed on Aldeyra Therapeutics' website under the Investors & Media section.

How long will the fireside chat be available for viewing?

The event will be archived on the website for 90 days.

What are the main investigational compounds of Aldeyra Therapeutics?

Aldeyra is developing reproxalap and ADX-629, which target reactive aldehyde species in inflammatory diseases.

What diseases are being targeted by Aldeyra's investigational compounds?

The compounds target immune-mediated diseases, including dry eye disease and allergic conjunctivitis.